RTX-321 Monotherapy in Patients With HPV 16+ Tumors

PHASE1TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

April 8, 2021

Primary Completion Date

November 30, 2022

Study Completion Date

November 30, 2022

Conditions
Cervical CancerHead and Neck CancerAnal Cancer
Interventions
DRUG

RTX-321

RTX-321 monotherapy

Trial Locations (10)

10016

Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York

15232

UPMC Hillman Cancer Center, Pittsburgh

19107

Thomas Jefferson University, Philadelphia

22031

Virginia Cancer Specialists, Fairfax

35249

University of Alabama, Birmingham

37203

Sarah Cannon Research Institute, Nashville

63110

Washington University, St Louis

73104

OU Health Stephenson Cancer Center, Oklahoma City

80045

University of Colorado Cancer Center, Aurora

90025

The Angeles Clinic & Research Institute, Los Angeles

Sponsors
All Listed Sponsors
lead

Rubius Therapeutics

INDUSTRY